Retatrutide Side Effects
Retatrutide is an investigational triple agonist (GLP-1 / GIP / glucagon). Its side-effect profile resembles the GLP-1 class plus glucagon-specific effects - notably a small resting-heart-rate rise seen in trials.
When they appear & how long they last
Phase 2 data showed dose-dependent GI effects concentrated during escalation, plus a modest heart-rate increase. Because retatrutide is not FDA-approved and most access is research-grade, side-effect monitoring matters more here, not less.
Commonly reported Retatrutide side effects
Dose-dependent, heaviest during escalation - the dominant Phase 2 finding.
Reported more than constipation in trial data.
At higher doses during rapid escalation.
A 4-6 bpm rise seen in Phase 2, attributed to glucagon-receptor activity.
The intended effect; the strongest single-compound weight effect published.
When to contact your provider
- Sustained resting heart rate elevated well above your baseline
- Severe abdominal pain radiating to the back - pancreatitis warning sign
- Persistent vomiting with dehydration
- Chest discomfort, palpitations, or shortness of breath
- Any allergic-reaction signs
Biomarkers worth tracking on Retatrutide
These catch issues early - before you feel them. Pull a baseline before you start, then re-check on the cadence noted below.
The glucagon-driven RHR rise is the signature retatrutide signal to watch.
Confirms the metabolic response.
Glucagon activity makes hepatic-enzyme monitoring worthwhile.
How to actually track Retatrutide side effects
Retatrutide is the clearest case for tracking: an investigational compound where you are the monitoring system. Log resting heart rate daily (any wearable works), plot it against your dose timeline, and pull ALT + fasting insulin at baseline and at each dose plateau. The RHR trend in particular tells you whether the glucagon component is pushing your cardiovascular load.
Track Retatrutide with MyProtocolStack →